Long-term use of antihypertensive drugs and risk of cancer

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 11, 2008, Pages 1039-1049

  Assimes, Themistocles L ^a,b,d   Elstein, Eleanor ^b   Langleben, Adrian ^b   Suissa, Samy ^b,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antihypertensive agents; Epidemiology; Neoplasms; Pharmacoepidemiology; Population

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; RENIN INHIBITOR; THIAZIDE DIURETIC AGENT;

ARTICLE; CANCER MORTALITY; CANCER RISK; CASE CONTROL STUDY; COLON CANCER; CONTROLLED STUDY; DRUG CLASSIFICATION; DRUG EXPOSURE; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERTENSION; LONG TERM CARE; LUNG CANCER; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT DURATION;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; ODDS RATIO; RISK ASSESSMENT; RISK FACTORS; SODIUM CHLORIDE SYMPORTER INHIBITORS; TIME FACTORS;

EID: 57649235888     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1656     Document Type: Article

References (45)

1. Kaplan NM, Flynn JT. Kaplan's Clinical Hypertension (9th edn). Lippincott Williams & Wilkins: Philadelphia, 2006.
2. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112: e154-e235.
3. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006; 8: 651-745.
4. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e385-e484.
5. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43: 10-17.
6. Borzecki AM, Oliveria SA, Berlowitz DR. Barriers to hypertension control. Am Heart J 2005; 149: 785-794.
7. Miller NH, Hill M, Kottke T, Ockene IS. The multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionals. Circulation 1997; 95: 1085-1090.
8. Psaty BM, Furberg CD. COX-2 inhibitors-lessons in drug safety. N Engl J Med 2005; 352: 1133-1135.
9. Pahor M, Guralnik JM, Ferrucci L, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996; 348: 493-497.
10. Pahor M, Guralnik JM, Salive ME, Corti MC, Carbonin P, Havlik RJ. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996; 9: 695-699.
11. Grossman E, Messerli FH, Goldbourt U. Antihypertensive therapy and the risk of malignancies. Eur Heart J 2001; 22: 1343-1352.
12. Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998; 352: 179-184.
13. Li CI, Malone KE, Weiss NS, Boudreau DM, Cushing-Haugen KL, Daling JR. Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65-79 years. Cancer 2003; 98: 1504-1513.
14. Largent JA, McEligot AJ, Ziogas A, et al. Hypertension, diuretics and breast cancer risk. J Hum Hypertens 2006; 20: 727-732.
15. Michels KB, Rosner BA, Walker AM, et al. Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of U.S. women: the nurses' health study. Cancer 1998; 83: 2003-2007.
16. Hole DJ, Gillis CR, McCallum IR, et al. Cancer risk of hypertensive patients taking calcium antagonists. Journal of Hypertension 1998; 16: 119-124.
17. Olsen JH, Sorensen HT, Friis S, et al. Cancer risk in users of calcium channel blockers. Hypertension 1997; 29: 1091-1094.
18. Meier CR, Derby LE, Jick SS, Jick H. Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch Intern Med 2000; 160: 349-353.
19. Friis S, Sorensen HT, Mellemkjaer L, et al. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer 2001; 92: 2462-2470.
20. Perron L, Bairati I, Harel F, Meyer F. Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control 2004; 15: 535-541.
21. Ronquist G, Rodriguez LA, Ruigomez A, et al. Association between captopril, other antihypertensive drugs and risk of prostate cancer. Prostate 2004; 58: 50-56.
22. Gonzalez-Perez A, Ronquist G, Garcia Rodriguez LA. Breast cancer incidence and use of antihypertensive medication in women. Pharmacoepidemiol Drug Saf 2004; 13: 581-585.
23. Fryzek JP, Poulsen AH, Lipworth L, et al. A cohort study of antihypertensive medication use and breast cancer among Danish women. Breast Cancer Res Treat 2006; 97: 231-236.
24. Vezina RM, Lesko SM, Rosenberg L, Shapiro S. Calcium channel blocker use and the risk of prostate cancer. Am J Hypertens 1998; 11: 1420-1425.
25. Rosenberg L, Rao RS, Palmer JR, et al. Calcium channel blockers and the risk of cancer. JAMA 1998; 279: 1000-1004.
26. Rothman KJ, Greenland S. (eds). Precision and validity in epidemiologic studies. In Modern Epidemiology (2nd edn). Lippincott-Raven: Philadelphia, 1998; 115-134.
27. Strom BL. Pharmacoepidemiology (4th edn). John Wiley: Chichester; Hoboken, NJ, 2005.
28. Saskatchewan Cancer Agency. Cancer Registry 2007, Vol. 2007. http://www.saskcancer.ca/Default.aspx?DN=e5d0bf2c-5345-4366-bbaa- c0562929c49c [Accessed on 28 August 2008].
29. Tonita J, Alvi R. Saskatchewan Cancer Control Report 2004: Profiling Cancer in Regional Health Authorities. Saskatchewan Cancer Agency: Regina, 2004.
30. Tonita J, Alvi R, Watson F, Robson D. Saskatchewan Cancer Control Report: Profiling Trends in Cancer, 1970-2001. Saskatchewan Cancer Agency: Regina, 2003.
31. Thomas DG. Algorithm AS-36. Exact confidence limits for the odds ratio in a 2 × 2 table. Appl Stat 1971; 20: 105-110.
32. Grossman E, Messerli FH, Boyko V, Goldbourt U. Is there an association between hypertension and cancer mortality? Am J Med 2002; 112: 479-486.
33. Yuan JM, Castelao JE, Gago-Dominguez M, Ross RK, Yu MC. Hypertension, obesity and their medications in relation to renal cell carcinoma. Br J Cancer 1998; 77: 1508-1513.
34. Chow WH, Gridley G, Fraumeni JF, Jr, Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med 2000; 343: 1305-1311.
35. Yu MC, Ross RK. Obesity, hypertension, and renal cancer. N Engl J Med 2001; 344: 531-532.
36. Fryzek JP, Poulsen AH, Johnsen SP, McLaughlin JK, Sorensen HT, Friis S. A cohort study of antihypertensive treatments and risk of renal cell cancer. Br J Cancer 2005; 92: 1302-1306.
37. Lilienfeld AM, Chang L, Thomas DB, Levin ML. Rauwolfia derivatives and breast cancer. Johns Hopkins Med J 1976; 139: 41-50.
38. Aromaa A, Hakama M, Hakulinen T, Saxen E, Teppo L, Ida lan-Heikkila J. Breast cancer and use of Rauwolfia and other antihypertensive agents in hypertensive patients: a nationwide case-control study in Finland. Int J Cancer 1976; 18: 727-738.
39. Labarthe DR, O'Fallon WM. Reserpine and breast cancer. A community-based longitudinal study of 2,000 hypertensive women. JAMA 1980; 243: 2304-2310.
40. Flegal KM, Brownie C, Haas JD. The effects of exposure misclassification on estimates of relative risk. Am J Epidemiol 1986; 123: 736-751.
41. Bourgault C, Rainville B, Suissa S. Antihypertensive drug therapy in Saskatchewan: patterns of use and determinants in hypertension. Arch Intern Med 2001; 161: 1873-1879.
42. Bourgault C, Senecal M, Brisson M, Marentette MA, Gregoire JP. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Hum Hypertens 2005; 19: 607-613.
43. Beiderbeck AB, Sturkenboom MC, Coebergh JW, Leufkens HG, Stricker BH. Misclassification of exposure is high when interview data on drug use are used as a proxy measure of chronic drug use during follow-up. J Clin Epidemiol 2004; 57: 973-977.
44. Friberg S, Mattson S. On the growth rates of human malignant tumors: implications for medical decision making. J Surg Oncol 1997; 65: 284-297.
45. Brambilla G, Martelli A. Genotoxicity and carcinogenicity studies of antihypertensive agents. Mutat Res 2006; 612: 115-149.